Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer

Journal of Andrology

Volumn 26, Issue 2, 2005, Pages 215-221

  Zeng, Hao ^a   Wu, Qi ^a   Li, Hong ^a   Wei, Qiang ^a   Lu, Yiping ^a   Li, Xiang ^a   Wang, Fang ^a   Zhao, Fujun ^a   Ding, Zhengyu ^a   Yang, Yuru ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Regulatory element

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LIPOSOME; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; DNA SEQUENCE; ENHANCER REGION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE AMPLIFICATION; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE ADENOCARCINOMA; RECOMBINANT PLASMID; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

EID: 20044369167     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2005.tb01088.x     Document Type: Article

References (32)

1. Bostwick DG, Pacelli A, Michael B, et al. Prostate specific membrane antigen expression in PIN and adenocarcinoma. Cancer. 1998;82:2256-2261.
2. Carter RE, Feldman AR, Coyle JT, et al. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptiase. Proc Natl Acad Sci U S A. 1996;93:749-753.
3. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192-3198.
4. Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology. 2001;57:801-805.
5. Denmeade SR, Sokoll LJ, Dalrymple S, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate. 2003;54:249-257.
6. Fair WR, Israeli RS, Heston WDW. Prostate-specific membrane antigen. Prostate. 1997;32:140-148.
7. Good D, Schwarzenberger P, Eastham JA, et al. Cloning and characterization of the prostate-specific membrane antigen promoter. J Cell Biochem. 1999;74:395-405.
8. Horoszewicz JS, Kawinki E, Murphy GP, et al. Monoclonal antibody to a new antigenic marker in epithelial prostatic cells and serum of prostate cancer patient. Anticancer Res. 1987;7:927-936.
9. Ikegami S, Tadakuma T, Suzuki S, et al. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res. 2002;93:1.154-1163.
10. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227-230.
11. Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-1811.
12. Kaighn ME, Narayan KS, Ohnuki Y, et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23.
13. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;57:2321-2324.
14. Latham JP, Searl PF, Mautner V, et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60:334-341.
15. Lee SJ, Kim HS, Yu R, et al. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther. 2002;6:415-421.
16. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634.
17. Meighan MA, Dickerson MT, Glinskii O, et al. Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen-PSMA) - cellular localization and bioactivity analyses. J Protein Chem. 2003;22:317-326.
18. Murphy G, ed. Models for Prostate Cancer. Vol 37. New York: Liss; 1980.
19. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002;285:247-256.
20. O'Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998;1443:113-127.
21. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-spcific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45:149-157.
22. Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression, of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IVô activity. J Biol Chem. 1999;274:8470-8483.
23. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-1451.
24. Silver DA, Pellicer I, Fair WR, et al. Prostate specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res. 1997;3:81-85.
25. Soule HD, Vazguez J, Long A, et al. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51:1409-1416.
26. Stone KR, Mickey DD, Wunderli H, et al. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21:274-281.
27. Troyer JK, Beckett ML, Wright GL Jr, et al. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and bodyfluids. Int J Cancer. 1995;62:552-558.
28. Uchida A, O'Keefe DS, Bacich DJ, et al. Prostate-specific suicide therapy using the newly discovered PSMA enhancer. Proc Am Assoc Cancer Res. 2000;41:380.
29. Uchida A, O'Keefe DS, Bacich D, et al. In vivo suicide gene therapy model using a newly discovered prostate-specific antigen promoter/ enhancer: a potential alternative approach to androgen deprivation therapy. Urology. 2001;58(suppl 2A):132-139.
30. Watt FB, Brookes DE, Ho T, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene. Genomics. 2001;73:243-244.
31. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
32. Wright GL Jr, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1995;1:18-28.